Why cannabinoid breath tests may not detect impairment

This commentary examines the limitations of using breath-based cannabinoid detection as a measure of impairment. While the original study by Deeb et al. represents a technical advancement in breath analysis methods, this response highlights critical gaps: THC concentrations in biological samples cannot reliably predict impairment, according to existing clinical studies and government reports. The analysis raises important concerns about drawing forensic conclusions from breath cannabinoid levels, particularly in driving impairment cases where the stakes are high.

The commentary identifies several analytical and methodological weaknesses that undermine the study's interpretability. Key variables like cannabis dose, product potency, and individual inhalation patterns were not controlled, making it impossible to establish clear relationships between measured cannabinoid levels and actual impairment effects. Additionally, the chromatographic technique used showed subpar resolution (Rs ≈ 0.9), which raises concerns about accurately distinguishing between structurally similar cannabinoids and potential false identifications. These technical limitations are particularly troubling in forensic contexts where breath test results could influence legal consequences.

The letter underscores a fundamental disconnect in cannabinoid research: measuring something doesn't mean you're measuring what matters. Breath cannabinoid detection cannot serve as a reliable biomarker for impairment because THC presence in exhaled breath reflects recent consumption rather than cognitive or motor impairment. This distinction is crucial for public policy, law enforcement, and anyone concerned with fair and accurate impairment testing.